These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 34254494)

  • 1. Neonatal diabetes mellitus due to a new KCNJ11 mutation - 10 years of the patient`s follow-up.
    Ješić MD; Stock H; Zdravković V; Kovačević S; Savić M; Ješić MM
    Turk J Pediatr; 2021; 63(3):490-494. PubMed ID: 34254494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study.
    Bowman P; Sulen Å; Barbetti F; Beltrand J; Svalastoga P; Codner E; Tessmann EH; Juliusson PB; Skrivarhaug T; Pearson ER; Flanagan SE; Babiker T; Thomas NJ; Shepherd MH; Ellard S; Klimes I; Szopa M; Polak M; Iafusco D; Hattersley AT; Njølstad PR;
    Lancet Diabetes Endocrinol; 2018 Aug; 6(8):637-646. PubMed ID: 29880308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved motor development and good long-term glycaemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation in the KCNJ11 gene.
    Slingerland AS; Nuboer R; Hadders-Algra M; Hattersley AT; Bruining GJ
    Diabetologia; 2006 Nov; 49(11):2559-63. PubMed ID: 17047922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful sulfonylurea treatment of a neonate with neonatal diabetes mellitus due to a new KCNJ11 mutation.
    Ješić MM; Ješić MD; Maglajlić S; Sajić S; Necić S
    Diabetes Res Clin Pract; 2011 Jan; 91(1):e1-3. PubMed ID: 21056492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diabetes and hypoglycaemia in young children and mutations in the Kir6.2 subunit of the potassium channel: therapeutic consequences.
    Flechtner I; de Lonlay P; Polak M
    Diabetes Metab; 2006 Dec; 32(6):569-80. PubMed ID: 17296510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful transfer to sulfonylureas in KCNJ11 neonatal diabetes is determined by the mutation and duration of diabetes.
    Babiker T; Vedovato N; Patel K; Thomas N; Finn R; Männikkö R; Chakera AJ; Flanagan SE; Shepherd MH; Ellard S; Ashcroft FM; Hattersley AT
    Diabetologia; 2016 Jun; 59(6):1162-6. PubMed ID: 27033559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outpatient transition of an infant with permanent neonatal diabetes due to a KCNJ11 activating mutation from subcutaneous insulin to oral glyburide.
    Bremer AA; Ranadive S; Lustig RH
    Pediatr Diabetes; 2008 Jun; 9(3 Pt 1):236-9. PubMed ID: 18221420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Permanent neonatal diabetes by a new mutation in KCNJ11: unsuccessful switch to sulfonylurea.
    Lau E; Correia C; Freitas P; Nogueira C; Costa M; Saavedra A; Costa C; Carvalho D; Fontoura M
    Arch Endocrinol Metab; 2015 Dec; 59(6):559-61. PubMed ID: 26331221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term response to sulfonylurea in a patient with diabetes due to mutation in the KCNJ11 gene.
    Vendramini MF; Gurgel LC; Moisés RS
    Arq Bras Endocrinol Metabol; 2010 Nov; 54(8):682-4. PubMed ID: 21340152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sulfonylurea improves CNS function in a case of intermediate DEND syndrome caused by a mutation in KCNJ11.
    Mlynarski W; Tarasov AI; Gach A; Girard CA; Pietrzak I; Zubcevic L; Kusmierek J; Klupa T; Malecki MT; Ashcroft FM
    Nat Clin Pract Neurol; 2007 Nov; 3(11):640-5. PubMed ID: 17982434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KCNJ11 in-frame 15-bp deletion leading to glibenclamide-responsive neonatal diabetes mellitus in a Chinese child.
    Yang W; Wei H; Sang Y
    J Pediatr Endocrinol Metab; 2013; 26(7-8):743-6. PubMed ID: 24266052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of KCNJ11 gene mutations in a family with neonatal diabetes mellitus: implications for therapeutic management of family members with long-standing disease.
    Abbasi F; Saba S; Ebrahim-Habibi A; Sayahpour FA; Amiri P; Larijani B; Amoli MM
    Mol Diagn Ther; 2012 Apr; 16(2):109-14. PubMed ID: 22471336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful transfer from insulin to oral sulfonylurea in a 3-year-old girl with a mutation in the KCNJ11 gene.
    Al-Mahdi M; Al Mutair A; Al Balwi M; Hussain K
    Ann Saudi Med; 2010; 30(2):162-4. PubMed ID: 20220270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transient neonatal diabetes with two novel mutations in the KCNJ11 gene and response to sulfonylurea treatment in a preterm infant.
    Siklar Z; Ellard S; Okulu E; Berberoğlu M; Young E; Savaş Erdeve S; Mungan IA; Hacihamdioğlu B; Erdeve O; Arsan S; Oçal G
    J Pediatr Endocrinol Metab; 2011; 24(11-12):1077-80. PubMed ID: 22308870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sulfonylurea vs insulin therapy in individuals with sulfonylurea-sensitive permanent neonatal diabetes mellitus, attributable to a KCNJ11 mutation, and poor glycaemic control.
    Stanik J; Dankovcikova A; Barak L; Skopkova M; Palko M; Divinec J; Klimes I; Gasperikova D
    Diabet Med; 2018 Mar; 35(3):386-391. PubMed ID: 29278452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful sulfonylurea treatment of a neonate with neonatal diabetes mellitus due to a novel missense mutation, p.P1199L, in the ABCC8 gene.
    Oztekin O; Durmaz E; Kalay S; Flanagan SE; Ellard S; Bircan I
    J Perinatol; 2012 Aug; 32(8):645-7. PubMed ID: 22842804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case report: Better late than never, but sooner is better: switch from CSII to sulfonylureas in two patients with neonatal diabetes due to KCNJ11 variants.
    Mancioppi V; Pozzi E; Zanetta S; Missineo A; Savastio S; Barbetti F; Mellone S; Giordano M; Rabbone I
    Front Endocrinol (Lausanne); 2023; 14():1143736. PubMed ID: 37251668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional effects of mutations at F35 in the NH2-terminus of Kir6.2 (KCNJ11), causing neonatal diabetes, and response to sulfonylurea therapy.
    Proks P; Girard C; Baevre H; Njølstad PR; Ashcroft FM
    Diabetes; 2006 Jun; 55(6):1731-7. PubMed ID: 16731836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sulfonylurea treatment outweighs insulin therapy in short-term metabolic control of patients with permanent neonatal diabetes mellitus due to activating mutations of the KCNJ11 (KIR6.2) gene.
    Tonini G; Bizzarri C; Bonfanti R; Vanelli M; Cerutti F; Faleschini E; Meschi F; Prisco F; Ciacco E; Cappa M; Torelli C; Cauvin V; Tumini S; Iafusco D; Barbetti F;
    Diabetologia; 2006 Sep; 49(9):2210-3. PubMed ID: 16816952
    [No Abstract]   [Full Text] [Related]  

  • 20. First case of neonatal diabetes with KCNJ11 Q52R mutation successfully switched from insulin to sulphonylurea treatment.
    Ioacara S; Flanagan S; Fröhlich-Reiterer E; Goland R; Fica S
    J Diabetes Investig; 2017 Sep; 8(5):716-719. PubMed ID: 28083968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.